Cite
MLA Citation
James P Buteau et al.. “PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.” Lancet oncology, vol. 23, no. 11, 2022, pp. 1389–1397. http://access.bl.uk/ark:/81055/vdc_100168599634.0x000015